Epizyme stock: buy or sell?
August 22nd, 2019
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States.
Should I buy Epizyme stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Epizyme stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Epizyme stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 6 ratings published for EPZM stock in the last month. The general sentiment of these ratings is bullish for EPZM stock, with 6 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-1-7||Leerink Swann||Market Perform||Outperform|
Epizyme stock analysis
Epizyme shares dropped -2.21% to $13.28 today.
Epizyme closed today at $13.28 and dropped a tragic -2.21%. On April, SMA100d and SMA200d crossed up triggering a rise of 4.73%. Since last Friday when EPZM stock price broke up the SMA100d line, it gained $0.45 (3.51%).
After boosting an amazing 16.18% in a week last week, Epizyme closed this week at $13.28 and eased a tragic -3.21%. Early August EPZM plummed a dreadful -6.09% in just one week.
Since early April when SMA20w and SMA40w crossed up, EPZM price slipped $-0.36 per share (-2.64%). Since early February when EPZM stock price broke up the SMA40w line, it gained $2.61 (24.46%).
Epizyme stock price history
Epizyme IPO was on May 31st, 2013 at $20.00 per share1. Since then, EPZM stock declined a -33.60%, with a yearly average of -5.60%.
1: Adjusted price after possible price splits or reverse-splits.
Epizyme stock historical price chart
EPZM stock reached 52-week highs on June at $16.59, and all-time highs 2013-07-17 with a price of 45.72.
Epizyme stock price target is $20.50Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 4 price forecasts for Epizyme stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-24||HC Wainwright||Set Price Target||n/a||$25.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Epizyme failed to meet the forecasts of the experts and posted a frightening EPS of $-0.29 per share when experts were expecting $-0.49.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Epizyme annual sales climbed a super good 117.00% to $21.70 M dollars from $10.00 marked in 2017. When comparing 2018 vs 2017, in line, profit margin (that is, the net income divided by revenues) skyrocketed a 773.37% to -569.72%.
|2013||$68 M||-||$-3.48 M-5.1%||-|
|2014||$41 M||-39.53%||$-55.01 M-132.8%||1,480.60%|
|2015||$2.56 M||-93.82%||$-132.38 M-5170.9%||140.66%|
|2016||$8.01 M||212.77%||$-110.21 M-1376.4%||-16.74%|
|2017||$10 M||24.89%||$-134.31 M-1343.1%||21.86%|
|2018||$22 M||117.00%||$-123.63 M-569.7%||-7.95%|
Quarterly financial resultsEpizyme posted $9.70 M in revenues for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter earnings marked $-22.95 million with a profit margin of -236.55%. Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Epizyme sales marked an amazing increase and boosted a inf%.
|2017-Q2||$10 M||-||$-28.02 M-280.2%||-|
|2018-Q2||$12 M||20.00%||$-29.13 M-242.7%||3.95%|
|2018-Q4||$10 M||-19.17%||$-22.95 M-236.5%||-21.23%|
Epizyme ownershipWhen you are planning to invest in shares of a company, it's worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Epizyme, 4.94% of all outstanding shares are owned by its staff.
Bearish positions for EPZM stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$922.7 M||$149.4 B||$67.1 B||$0.0 M||$102.0 B|
|Total shares||69.5 M||1,760.0 M||701.0 M||0.0 M||2,490.0 M|
|Float shares||76.3 M||1,750.0 M||706.3 M||13.9 M||2,440.0 M|
|- Institutional holdings (%)||93.2%||76.5%||77.6%||8.1%||11.0%|
|- Insider holdings (%)||4.9%||0.7%||0.2%||16.9%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$13.02 - $13.60|
|Average true range||$0.77|
|50d mov avg||$13.03|
|100d mov avg||$12.92|
|200d mov avg||$11.23|
Epizyme performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Epizyme against , Celgene, Dare Bioscience, GlaxoSmithKline, Novartis and Seattle Genetics in the following table: